Drug Profile
SC 106
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Leukotriene receptor antagonists; Prostaglandin synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Jul 2000 Discontinued-II for Rheumatoid arthritis in United Kingdom (PO)
- 11 Jun 1997 Phase-II clinical trials for Rheumatoid arthritis in United Kingdom (PO)
- 02 Oct 1996 SC 106 is to be out-licensed by Scotia